Option Deal Structure Works For Myriad As It Moves To Buy Crescendo

Having watched Crescendo Bioscience gain a foothold in the market for inflammatory and autoimmune diagnostics, Myriad Genetics is now moving to acquire the company – a right it obtained via a novel strategic investment agreement in 2011.

When Myriad Genetics Inc. crafted a strategic investment agreement with an option-to-purchase with Crescendo Bioscience Inc. in September 2011, the company emphasized its desire to diversify both in terms of therapy area (beyond oncology) and technology (into protein-based testing) while maintaining the younger company’s independence and giving it time to prove itself. (See Also see "Myriad Genetics' M&A Buys Into Protein-Based Testing" - Scrip, 1 October, 2011..) Having watched Crescendo gain a foothold in the market for inflammatory and autoimmune diagnostics – it had launched its first test, Vectra DA, for measuring disease activity in rheumatoid arthritis (RA) patients, in November 2010 – Myriad is now moving forward with the acquisition. [See Deal] Myriad first came to know Crescendo when a mutual acquaintance brought together Crescendo president and CEO William Hagstrom and Myriad Genetic Laboratories Inc. president Mark Capone at the JP Morgan Healthcare Conference in January 2011. Their interests clicked. “Those that have longer-term interests in building positions in markets [can benefit] from creative deal structures,” Hagstrom says. “There hadn’t been one structured in quite this way before.”

The agreement included a $25 million loan – nondilutive financing that was to be repaid in years four to six...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Deals Shaping The Industry, June 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.